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Mayaro virus (MAYV), an Aedes mosquito–borne alphavirus, 
is endemic to Brazil and other South America countries. We 
investigated dengue- and chikungunya-negative febrile pa-
tients visiting rural areas near Goiânia, Goiás, and found a 
high proportion (55%) of MAYV IgM. Our findings suggest 
the presence of highly endemic foci of MAYV in central Brazil.
Mayaro virus (MAYV) is an Aedes mosquito–borne al-phavirus of the New World, transmitted mainly by 
tree canopy–dwelling Haemagogus spp. mosquitoes, was 
discovered in Trinidad in 1954. MAYV causes a dengue-
like acute febrile illness with arthralgic manifestations (1). 
Exposure to MAYV has been reported in several countries 
of Central and South America, and Mayaro fever has been 
identified in French Guiana, Suriname, Venezuela, Peru, Bo-
livia, and Brazil (2,3). In Brazil, Mayaro fever has been re-
ported in the Amazon region (2,4) and in Mato Grosso (5,6).
At the end of 2014, after chikungunya virus (CHIKV) 
spread in South America, the Brazil Ministry of Health 
enhanced the surveillance system for dengue-like illness. 
Accordingly, febrile patients attending primary care cen-
ters are tested for dengue virus (DENV) infection by using 
viral antigen (NS1), virus isolation, or reverse transcription 
PCR (up to 5 days after symptom onset), and/or ELISA for 
IgM (after the sixth day). DENV-negative patients fitting 
the clinical and epidemiologic criteria for chikungunya set 
by the Ministry of Health (http://www.saude.gov.br) are 
notified to the Center for Strategic Information in Health 
Surveillance of Goiânia city for further investigation. 
Blood samples collected during June 1, 2014–June 30, 
2015, were stored at –20°C and sent to the Department of 
Arbovirology and Hemorrhagic Fevers, Instituto Evandro 
Chagas (Belém, Brazil), to be evaluated for CHIKV by an 
IgM-capture ELISA (MAC ELISA; Centers for Disease 
Control and Prevention, Atlanta, GA, USA). A subsample 
of CHIKV-negative serum collected during December 
2014–June 2015 was tested by hemagglutination inhibition 
(HI) (7) against the most common arboviruses. We evaluat-
ed serum samples with monotypical or heterotypic reactiv-
ity to alphaviruses, with HI titers >40 using an IgM MAC 
ELISA for MAYV, as described by Kuno (8) and then mod-
ified (9). The results were sent to the Center for Strategic 
Information in Health Surveillance for further clinical and 
epidemiologic investigations.
We tested 75 samples from DENV-negative patients 
for CHIKV. Five of the 31 DENV-negative persons from 
whom serum was collected during June–December 2014 
and none of the 44 from January–June 2015 were positive 
for CHIKV IgM. Two additional samples yielded indeter-
minate results for CHIKV.
Of 27 CHIKV-negative samples tested by HI, 16 
were reactive to alphaviruses (median titer 160 [range 
80–1,280]); of these, 15 (56%) were confirmed as positive 
by IgM MAC ELISA for MAYV, and 1 sample was bor-
derline. The median interval between symptom onset and 
serum collection was 37 days (range 12–167 days).
Patients were a median of 45 years of age (range 30–70 
years). Fourteen were women. Patients’ educational level 
was high; 11 (73%) patients had >8 years’ education, and 
47% had >12 years’ education.
All the patients with an antibody profile suggesting 
recent MAYV infection resided in Goiânia but had trav-
eled to rural areas in the 15 days before symptom onset. 
Twelve patients had visited farms or small holdings in the 
forests around towns located 34 km (Hidrolandia) and 46 
km (Bela Vista) from Goiânia (online Technical Appendix 
Figure, https://wwwnc.cdc.gov/EID/article/23/6/16-0929-
Techapp1.pdf). In particular, 7 patients had been around 
Bela Vista and 5 in the area of Hidrolandia, whereas only 1 
had been near Pontalina and 2 in Itacaja (Tocantins), which 
is outside the state of Goiás. Ten of these 11 patients re-
ported engaging in recreational activities.
The high frequency of MAYV IgM detection among 
febrile patients in Goiânia is surprising. Identification of 
recent infections most likely acquired in rural areas and 
forests around the city of Goiânia indicates the existence 
of active foci where a sylvatic cycle of MAYV is estab-
lished. The MAYV belt around Goiânia, where epizoot-
ics of jungle yellow fever were also reported (http://www.
paho.org/hq/index.php?option=com_docman&task=doc_
view&Itemid=270&gid=34247&lang=en), is represented 
by a wet area hosting small primates, which may play a 
role as virus amplifier.
Our conclusions are subject to several limitations. 
First, selection bias could affect findings regarding the 
proportion of MAYV recent infections because of the lack 
of systematic testing for dengue-like illness. Second, we 
did not conduct PCR to identify acute infections because 
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the samples were collected after the viremic phase. Third, 
plaque-reduction neutralization testing was not performed, 
and because of the lack of convalescent serum, IgG sero-
conversion or titer increase were not evaluated; however, 
MAC ELISA is considered a valid technique for diagnos-
ing recently acquired infection with MAYV (10). Finally, 
the frequency of rash (Table), higher than in other case se-
ries (4), might be overestimated because of stringent selec-
tion criteria used for MAYV testing.
In conclusion, infection with MAYV occurs more 
frequently than expected in central Brazil. Mayaro fever 
should be considered in the differential diagnosis with 
DENV, CHIKV, and Zika virus infections in areas charac-
terized by arbovirus cocirculation.
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In March 2014, the World Health Organization declared an 
outbreak of Ebola virus disease in Guinea. In August 2014, 
a case caused by virus imported from Guinea occurred in 
Senegal, most likely resulting from nonsecure funerals and 
travel. Preparedness and surveillance in Senegal probably 
prevented secondary cases. 





Table. Clinical characteristics of 15 patients positive for IgM 
against Mayaro virus, Goiânia, Goiás, Brazil, June 2014– 
June 2015 
Sign or symptom No. (%) patients 
Fever 15 (100) 
Arthralgia 14 (93) 
Joint edema 14 (93) 
Rash 14 (93) 
Headache 13 (87) 
Weakness 13 (87) 
Myalgia 12 (80) 
Eye pain 8 (53) 
Icterus 4 (27) 
Photophobia 3 (20) 
Severe itching 3 (20) 
Lymphadenopathy 2 (13) 
Vomiting 2 (13) 
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